{"id":65331,"date":"2021-05-15T14:58:15","date_gmt":"2021-05-15T18:58:15","guid":{"rendered":"http:\/\/stateofthenation.co\/?p=65331"},"modified":"2021-05-15T15:00:59","modified_gmt":"2021-05-15T19:00:59","slug":"10570-dead-405259-injuries","status":"publish","type":"post","link":"https:\/\/stateofthenation.co\/?p=65331","title":{"rendered":"10,570 DEAD 405,259 INJURIES"},"content":{"rendered":"

10,570 DEAD 405,259 Injuries: European Database of Adverse Drug Reactions for COVID-19 \u201cVaccines\u201d<\/strong><\/h1>\n

<\/p>\n

\"\"<\/p>\n

by\u00a0Brian Shilhavy
\nEditor, Health Impact News<\/p>\n

The European database of suspected drug reaction reports is\u00a0EudraVigilance,<\/a>\u00a0which also tracks reports of injuries and deaths following the experimental COVID-19 \u201cvaccines.\u201d<\/p>\n

Here is what\u00a0EudraVigilance<\/a>\u00a0states about their database:<\/p>\n

This website was launched by the\u00a0European Medicines Agency<\/a>\u00a0in 2012\u00a0to provide public access to reports of suspected side effects\u00a0<\/strong>(also known as suspected adverse drug reactions). These reports are submitted electronically to\u00a0EudraVigilance<\/a>\u00a0by national medicines regulatory authorities and by pharmaceutical companies that hold marketing authorisations (licences) for the medicines.<\/p>\n

EudraVigilance is a system designed for collecting reports of suspected side effects. These reports are used for evaluating the benefits and risks of medicines during their development and monitoring their safety following their authorisation in the European Economic Area (EEA).\u00a0EudraVigilance has been in use since December 2001.<\/p>\n

This website was launched to comply with the\u00a0EudraVigilance Access Policy<\/a>, which was developed to improve public health by supporting the monitoring of the safety of medicines and to increase transparency for stakeholders, including the general public.<\/p>\n

The\u00a0Management Board of the European Medicines Agency<\/a>\u00a0first approved the EudraVigilance Access Policy in December 2010.\u00a0A revision was adopted by the Board in December 2015 based on the 2010 pharmacovigilance legislation.<\/span>\u00a0The policy aims to provide stakeholders such as national medicines regulatory authorities in the EEA, the European Commission, healthcare professionals, patients and consumers, as well as the pharmaceutical industry and research organisations, with access to reports on suspected side effects.<\/p>\n

Transparency is a key guiding principle of the Agency, and is pivotal to building trust and confidence in the regulatory process. By increasing transparency, the Agency is better able to address the growing need among stakeholders, including the general public, for access to information. (Source<\/a>.)<\/p><\/blockquote>\n

Their report through May 8, 2021 lists\u00a010,570 deaths and 405,259 injuries<\/strong>\u00a0following injections of four experimental COVID-19 shots:<\/p>\n